Engflag

Eumocream 25%

Quick links to important sections

Eumocream 25%

There is no image.

Method of action: Laxative

Treatment option: Sore Throat, Constipation

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eumocream 25%

Property Description
Active Ingredient Glycerol (INN: Glycerin)
Form Cream (Semi-solid dosage form)
Pharmacological Class Humectant, Emollient
Route of Administration Topical (Applied to skin surface)
Origin Derived (Natural/Synthetic sources)

What Type of Medicine is Eumocream 25%?

Eumocream 25% is a specific dermatological preparation, classified as a single-ingredient medicine formulated as a cream for topical administration. It is placed within the humectant and emollient pharmacological classes, which are widely recognized for their application in moisture therapy. The cream base, an emulsion of lipids and water, provides a balance between substantial skin coverage and patient comfort. Glycerol, as the active substance, is recognized as an effective humectant for its role in skin hydration.

What is the Active Ingredient and Concentration (25%)?

The defining feature of this preparation is its use of Glycerol (INN: Glycerin) as the sole active compound, present at a concentrated 25%. Glycerol, a trihydroxy alcohol, possesses a unique chemical structure that allows it to attract and bind water molecules efficiently. This high concentration is a distinctive feature that positions Eumocream 25% for intensive therapeutic use, contrasting with many standard emollients where Glycerol functions merely as a low-level excipient. Glycerol and related compounds are essential for maintaining the physiological and biochemical integrity of the epidermis, underscoring the compound's integral role in skin function, whether derived from natural or synthetic processes.

What is the Primary Purpose of a Glycerol Emollient Cream?

The primary purpose of Eumocream 25% is to provide intensive hydration therapy to address conditions of skin dryness. The active humectant mechanism works to restore vital moisture content in the epidermis by actively attracting and binding water molecules. This action alleviates the scaling, tightness, and discomfort commonly associated with dry skin conditions and xerosis. Its general use involves supporting the continuous repair and maintenance of the skin’s natural barrier function, thereby improving overall elasticity and resilience.

Regulatory References

  1. derived from natural or synthetic processes

What side effects are possible with Eumocream 25%?

Possible Side Effects and Safety Information

The safety profile for Eumocream 25%, a topical dermatological preparation containing Glycerol, is defined primarily by potential localized skin reactions. Official regulatory labeling generally does not assign standardized frequency categories (e.g., 'common,' 'uncommon') to these occurrences.

Adverse Reaction Scope

The most commonly documented adverse reactions are confined to the Skin and subcutaneous tissue disorders. These potential local effects include irritation, rash, localized swelling, and itching at the application site. While not often quantified by frequency, the appearance of any such reaction in real clinical use requires the cessation of application, as stated in regulatory documents.

Serious Adverse Reactions and Safety Restrictions

The most critical safety event documented in official labeling is the potential for Hypersensitivity or generalized allergic reactions. Should signs of hypersensitivity develop, this warrants immediate discontinuation of product use.

Official labeling defines specific restrictions regarding the condition of the skin where the product is applied. Eumocream 25% should not be used on skin that is already damaged, broken, scarred, or affected by pre-existing skin conditions such as dermatitis or eczema. Additionally, a contextual safety note indicates the possibility of abnormal reactions on the skin due to direct sunlight, which is a high-level safety consideration for use.

Regulatory Safety Summary

Classification Detail (Based on Regulatory Documents)
System-Organ Class Skin and subcutaneous tissue disorders
Serious Reaction Hypersensitivity / Allergic reactions
Safety Limitation Do not apply to damaged or broken skin
Population-Specific Notes None explicitly defined in official labels

This official safety information structures the understanding of risk, emphasizing that documented risks are localized to the skin and are governed by the condition of the skin's surface prior to application. The most significant safety concern is the potential for hypersensitivity.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is strictly based on documented data found in government regulatory labeling (e.g., Summary of Product Characteristics, FDA Prescribing Information).

Regulatory Focus Official Documented Information
Exposure Risks Systemic overdose manifestations are not expected from the intended topical application route due to minimal absorption. Overdose from excessive skin application is limited to an increase in the incidence and severity of local skin reactions.
Systemic Manifestations The severe overdose risk is associated with accidental oral ingestion. Documented systemic effects include headache, nausea, vomiting, diarrhoea, thirst, dizziness, and mental confusion. More severe outcomes have been officially reported, such as cardiac arrhythmias, hyperglycaemia, and severe dehydration.
Emergency Actions Immediate medical attention or contacting a Poison Control Center is required for any case of accidental ingestion. The management specified in regulatory labeling is symptomatic and supportive therapy, which may include gastric lavage if ingestion is recent. No specific antidote is documented for Glycerol overdose.

Official Overdose Statements

  • Overdose resulting from excessive topical application is limited to the local increase in the incidence and severity of local skin reactions.
  • Accidental oral ingestion of large amounts requires seeking immediate medical attention due to the potential for serious systemic effects, including cardiac arrhythmias, hyperglycemia, and severe dehydration.
  • Treatment is specified as symptomatic and supportive therapy.

Connection to the overall overdose profile: Regulatory documents establish a clear distinction: the intended topical use poses a minimal systemic risk, leading only to local skin manifestations. The documented severe risk is tied solely to accidental oral exposure, which mandates immediate medical intervention due to the potential for severe outcomes, requiring regulator-described supportive measures.

Therapeutic Uses of Eumocream 25%

Quick Facts

  • Aids in the management of dry, sensitive, and itchy skin.
  • Provides moisturizing support for skin prone to eczema and dermatitis.
  • Assists in maintaining the skin barrier function.
  • Offers relief from discomfort associated with common dry skin conditions.

What Eumocream 25% Treats: Main Uses and Benefits

Eumocream 25% is a topical preparation that supports the management of various dry skin conditions. Its primary purpose is to act as a hydrating emollient, a component of a comprehensive approach to skin health. The application of this cream may help to alleviate the dryness, scaling, and associated discomfort of sensitive and irritated skin.

It contributes to the relief of symptoms associated with chronic dry skin, including those prone to eczema and dermatitis. Eumocream 25% assists in maintaining the skin's moisture level by drawing and retaining water, which is important for skin barrier function. This formulation is often used as a daily maintenance treatment to support the ongoing care of skin vulnerable to dryness and associated irritation.

Eligibility and Restrictions for Use

Who Can and Cannot Use This Medicine

The following eligibility information is derived from official government regulatory documents for Clobetasone Butyrate 0.05% Cream (often associated with the Eumovate brand), which is a licensed medicinal product. This profile defines the populations permitted, restricted, or prohibited from using the cream.

Populations Who Must Not Use (Contraindications)

Use of this medicine is strictly contraindicated in the following situations, as stated in the official labeling:

  • Known hypersensitivity or allergy to clobetasone butyrate or any of the inactive ingredients.
  • Presence of untreated infections of the skin (e.g., viral, fungal, or bacterial).
  • Skin conditions including rosacea, acne vulgaris, or pruritus without inflammation.

Restricted or Conditional Use

Official documents outline specific conditions and populations that require caution or medical supervision:

  • Children under 12 years of age must only use this cream on the advice of a doctor, and treatment should not normally exceed 7 days.
  • Pregnancy and Breastfeeding: Use is conditional and should only be considered if a doctor determines the potential benefit outweighs the risk. It must not be applied to the breasts during lactation.
  • Body Area Restrictions: The cream must not be applied to the face, groin, genitals, or between the toes.
  • Psoriasis: Not recommended for the treatment of psoriasis as it may lead to a rebound flare-up.

Users should adhere to the minimum quantity for the shortest duration necessary to achieve effect.

What should I know about interactions with other medicines?

Interactions with other medicines and products — Official Regulatory Information for Eumocream 25%

The officially documented interaction profile for Eumocream 25% is primarily defined by the topical route of administration and the resulting negligible systemic absorption of its active ingredient, Glycerol.

Interaction Scope Category Regulatory Information for Topical Glycerol 25%
Systemic Drug-Drug Interactions None documented. No clinically significant pharmacokinetic interactions (e.g., related to metabolic enzymes or transporters) are expected with medicines taken orally or intravenously.
Food, Alcohol, or Supplements None documented. Due to minimal absorption from the skin surface, no restrictions or cautions concerning ingestion of food, alcohol, or herbal products are established in regulatory labeling.
Interaction-Related Restrictions The only officially noted restriction is a local administration caution concerning other topical products.
Medicinal Product Categories Other topical dermatological preparations, including prescription creams and ointments.

Official Interaction Statements:

The systemic drug-drug interaction profile is classified as negligible, as the active substance does not reach a plasma concentration level sufficient to cause systemic interaction effects. This eliminates the need for documented warnings regarding CYP enzymes or drug transporters with internal medicines.

The only official constraint documented is the timing and location of application when co-administering with other topical medicines. Applying Eumocream 25% simultaneously with other topical treatments on the same skin area may theoretically alter the absorption or reduce the intended efficacy of the other preparation.

Connection to the Overall Interaction Profile:

Regulatory documents establish that the product's interaction structure is based on the absence of systemic interaction risk with oral medicines. Official cautions are limited to the procedural constraint of co-application with other topical preparations on the skin surface.

Mechanism of Action

How Eumocream 25% Works

The action of Eumocream 25% (Glycerol 25%) is purely peripheral and physico-chemical, achieved through the simultaneous engagement of three core mechanistic domains that modulate the skin's water content and structural integrity.

Active Water Acquisition and Reservoir Creation

This mechanism involves Glycerol’s high-affinity binding of water (humectancy) and its subsequent Facilitated Transport via Aquaporin-3 (AQP3) channels in the epidermis. By drawing water from the deeper layers and ambient air, this process establishes a stable hydration reservoir that contributes to the maintenance of the Epidermal Hydration Gradient, a core physiological requirement for barrier integrity.

Structural Modulation and Barrier Stabilization

The resulting increase in water content serves to plasticize the protein components and stabilize the Stratum Corneum (SC) Lipids within the outer layer. This structural modulation reinforces the physical structure of the skin barrier and reduces the rate of Transepidermal Water Loss (TEWL), resulting in altered mechanical properties of the skin surface, specifically increased flexibility and suppleness.

️ Regulation of Cell Shedding and Complementary Action

Adequate hydration optimizes the activity of pH-sensitive Corneodesmolytic Enzymes, which are essential for orderly desquamation (cell shedding). This mechanism is complemented by the emollient cream base, which acts as an occlusive layer to physically trap the water that Glycerol has pulled in, sustaining the moisture balance, supporting the physiological process of uniform cell shedding.

Dosage and Administration Information

How to Use Eumocream 25%

The use of Eumocream 25%, a specific dermatological preparation containing 25% Glycerol, is characterized by topical administration. This formulation is only applied to the skin surface; it is strictly for external use and must not be ingested.

Administration Principles

Usage follows a qualitative dosing approach rather than a measured numerical dosage. Application involves spreading a thin layer of the cream to the affected and adjacent areas of the skin.

The frequency pattern is structured as as-needed use, typically involving application multiple times daily to sustain skin hydration levels. A key procedural instruction is to apply the cream immediately after contact with water, such as following a bath or shower, onto cleansed skin. After application, the cream should be gently massaged into the skin until the product is fully absorbed.

Use Duration and Population

Eumocream 25% is primarily structured for long-term maintenance use, suitable for continuous application as part of an ongoing skin care protocol. While the general administration instructions apply to adults, adolescents, and children, use in infants under six months should be initiated only after medical consultation. Application is also constrained by the condition of the skin; the cream is generally not to be applied to skin that is broken or significantly damaged.

Recent Clinical Evidence

Research evidence / Overview of Studies for Eumocream 25%

Evidence for Use in General Skin Dryness (Xerosis)

Research was evaluated in settings that studied the effects of high-concentration glycerol preparations through Randomized Controlled Trials (RCTs) and scientific reviews. These studies primarily was observed in populations of healthy adult volunteers and adults experiencing chronic dry skin, including those with uremic xerosis. The trials examined outcomes related to physical discomfort and biophysical measurements, such as skin hydration levels and Transepidermal Water Loss (TEWL).

Trials reported measurements where changes in skin hydration was observed in some studies compared to a non-active cream base (vehicle). The data show patterns related to changes in clinical scoring scales for skin roughness and scaling. However, follow-up durations were limited in many primary clinical trials, meaning there is limited information for long-term outcomes and maintenance effects over many months.

Evidence for Use in Eczema-Prone Skin and Barrier Support

Research explored outcomes related to systemic or functional imbalance in conditions characterized by fluctuating or episodic manifestations, such as eczema-prone skin and Atopic Dermatitis (AD). Studies included RCTs and comparative trials involving adults and children with mild-to-moderate AD. Researchers assessed clinical severity using standardized tools (e.g., SCORAD score) and studied impaired skin barrier function using controlled models.

Studies report how symptoms evolved in the observed populations, noting that the application of the preparation was associated with improved skin hydration. In experimental settings of barrier damage, research describes that changes in the skin barrier's recovery was observed in some studies when compared to non-active treatments. Comparative evidence is lacking for how the preparation was evaluated directly against other optimized active emollients.

Research Gaps and What Remains Uncertain

The overall research contributes to the broader evidence landscape regarding symptom patterns and biophysical measurements. However, long-term effects are not fully established, as the duration of follow-up was limited in many studies. Furthermore, subgroup findings are uncertain, as data for certain groups remain insufficient, including the elderly. Certainty remains low regarding which part of the preparation was associated with patient-reported outcomes describing perceived discomfort, such as relief from itching.

Key Studies & References

  1. Glycerin Topical: Drug Information Overview
  2. Index of Randomized Controlled Trials and Reviews for Glycerin in Xerosis/Eczema (Research Index)

Frequently Asked Questions (FAQ)

Common questions about Eumocream 25% (FAQ)

Q: Can Eumocream 25% be used on sensitive areas like the face?

A: Official labeling for topical emollients often instructs users to check the product labeling for specific application site restrictions. The safety profile for the related Clobetasone Butyrate product explicitly contraindicates use on the face, groin, or genitals. This indicates that users are often instructed to check the product labeling for specific application site restrictions.

Q: Can Eumocream 25% be used at the same time as other topical products?

A: Regulatory documents state that simultaneous application with other topical medicines on the same skin area may theoretically alter the absorption or reduce the intended efficacy of the other preparation. This official caution is limited to the procedural constraint of co-application on the skin surface.

Q: Do I need to avoid sun exposure while using Eumocream 25%?

A: The official safety summary includes a contextual note regarding the possibility of abnormal reactions on the skin due to direct sunlight, which is a high-level safety consideration for use. The official documentation indicates users should refer to the product labeling for specific precautions regarding sun exposure.

Q: Are there any long-term side effects noted in official documentation for Eumocream 25%?

A: The official safety profile focuses on potential localized skin reactions such as irritation or rash, which are expected to be confined to the application site. Official safety documentation notes that the available research data is limited regarding long-term outcomes and maintenance effects.

Q: If I have kidney or liver problems, does that affect my eligibility for Eumocream 25%?

A: Regulatory documents establish that the product's interaction structure is based on the absence of systemic interaction risk with oral medicines. This is due to the negligible systemic absorption of the active ingredient from the skin surface, meaning no specific restrictions related to systemic organ function (such as kidney or liver issues) are documented in the labeling.

Q: What happens if I use more Eumocream 25% than the amount described in the instructions?

A: Official instructions define usage as a thin layer applied multiple times daily to the affected area. The preparation is strictly for external use and must not be ingested. Regulatory warnings exist regarding the risk of intoxication should the product be accidentally swallowed.

Q: What is the typical duration of treatment with Eumocream 25%?

A: The preparation is primarily structured for long-term maintenance use, suitable for continuous application as part of an ongoing skin care protocol. This type of use profile contrasts with the short, time-limited courses often advised for other types of dermatological products.

Q: Is it normal to feel a slight tingling sensation when I first apply the cream?

A: The official safety profile lists the most commonly documented local skin effects, which include irritation, rash, localized swelling, and itching at the application site. The occurrence of any such reaction in real clinical use requires the cessation of application, as stated in regulatory documents.

Q: Is Eumocream 25% safe for use during pregnancy?

A: Use during pregnancy and breastfeeding is classified as conditional in the official documentation. Regulatory documents state that use is conditional, and the assessment of potential benefit versus risk is made by a healthcare provider.

Q: What are the known potential interactions between Eumocream 25% and common supplements?

A: Regulatory documentation establishes no documented restrictions or cautions concerning the use of the product with food, alcohol, or herbal supplements. This is attributed to the minimal absorption of the active substance from the skin surface, which prevents systemic interaction effects.

Q: Does Eumocream 25% thin the skin if used for a long period?

A: The active ingredient in Eumocream 25% is a humectant and emollient that works to improve skin hydration and reinforce the physical structure of the skin barrier. Official regulatory documents do not list skin thinning (atrophy) as a potential adverse reaction for this product’s pharmacological class.

Q: Does Eumocream 25% need to be refrigerated or is room temperature fine?

A: Official instructions for product stability define storage requirements to keep the cream below 25 C in its original container. It is also noted that the product should be protected from exposure to excessive heat and direct sunlight.

Q: Can Eumocream 25% be used by people with sensitive skin?

A: The product's primary purpose is to provide intensive hydration therapy for dry skin conditions. However, the safety profile notes that potential local effects can include irritation at the application site. If users experience irritation, this warrants the cessation of application, as stated in regulatory documents.

Q: Does using Eumocream 25% affect blood test results?

A: Regulatory documentation establishes that the systemic drug interaction profile is classified as negligible because the active substance does not reach a plasma concentration level sufficient to cause systemic interaction effects or affect internal blood chemistry measurements.

Q: What is the process for disposing of expired Eumocream 25%?

A: Official instructions state that unused medicine and packaging should be disposed of via your local pharmacist. This specialized disposal method is defined in the official instructions and required for all unused medicine, including expired product.

Q: Can Eumocream 25% be used on open wounds?

A: Official labeling provides a specific safety limitation: the cream should not be used on skin that is already damaged, broken, scarred, or affected by pre-existing skin conditions. The safety limitation stating the cream should not be used on broken or damaged skin includes conditions such as open wounds.

Q: How does the drug agency classify the overall safety of Eumocream 25%?

A: The product's overall safety is defined by the risk profile, which is confined primarily to potential localized skin reactions. The safety limitations emphasize that application is governed by the condition of the skin's surface prior to application, with the most critical safety concern being the potential for Hypersensitivity.

Q: Why do some people experience initial redness with Eumocream 25%?

A: The most commonly documented adverse reactions are confined to the skin and include irritation and rash at the application site. Official documents state that the appearance of any such reaction, including redness, requires the cessation of application.

Q: Is it possible to develop a tolerance to the effects of Eumocream 25% over time?

A: The official safety profile for the product does not describe the development of tolerance or tachyphylaxis, which are effects typically associated with different pharmacological classes. Research data on long-term effects remains limited in many primary clinical trials.

How should Eumocream 25% be stored and disposed of?

How to Store and Dispose of Eumocream 25%?

The official instructions for Eumocream 25% address product stability, child safety, and a critical fire hazard associated with emollient creams.

Storage and Stability Requirements Fire Safety and Disposal Constraints
Store the cream below 25 C in its original container. Avoid all naked flames and smoking while using the cream or wearing items that have contacted it.
Keep the tube tightly closed to protect the product integrity. Cream residue on fabrics (clothing, bedding, dressings) increases flammability risk, even after washing.
Keep this medicine out of the sight and reach of children. Dispose of unused medicine and packaging via your local pharmacist, not via household waste or wastewater.

Regulatory documents define specific handling rules to mitigate a serious fire hazard: the cream can transfer from the skin to fabrics, which then ignite more quickly and intensely upon contact with a heat source. Therefore, users must be explicitly warned to avoid any naked flames. The product must be stored below 25 C and disposed of according to environmental requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUnited Kingdom

Equivalent of Eumocream 25% found in:

A-Z Index: